4D Molecular Therapeutics, Inc.
No enriched coverage for $FDMT in the last 7 days.
No SEC Form 4 filings for $FDMT in the last 30 days.
This page from WaterWorld provides the latest news and stock information for 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT). It lists recent company announcements, financial results, clinical trial updates for gene therapies, and participation in investor conferences. The content includes details on stock performance and links to various news sources like MarketBeat, GlobeNewswire, and Benzinga.
This page provides a comprehensive resource for 4D Molecular Therapeutics (FDMT) SEC filings, including annual reports, quarterly earnings, material events, and insider trading forms. It highlights recent Form 8-K filings detailing clinical trial data, collaborations, and executive appointments. The platform also offers AI-powered summaries and sentiment analysis for these regulatory documents.
4D Molecular Therapeutics (FDMT) is rapidly advancing its 4D-150 programs for wet AMD and DME through phase 3 trials, driven by high demand from physicians and patients. The company has developed commercialization strategies for the U.S., Europe, and Asia-Pacific markets and is well-funded until 2028. Additionally, FDMT is progressing a promising cystic fibrosis program.
